Workup and Management of Anemia in Sickle Cell Trait with Elevated Erythropoietin
This patient with sickle cell trait (not disease), negative malignancy workup, and elevated erythropoietin requires investigation for causes of anemia other than the trait itself, as sickle cell trait alone does not cause clinically significant anemia.
Critical Distinction: Sickle Cell Trait vs. Disease
Sickle cell trait (HbAS) is a benign carrier state that does not cause anemia under normal physiological conditions 1. The presence of anemia with elevated erythropoietin (37.6 mU/mL, which is elevated but not extremely high) indicates another underlying cause must be identified.
Systematic Workup Approach
Iron Studies (Priority #1)
Check transferrin saturation (TSAT) and ferritin immediately 2, 3:
- Iron deficiency: TSAT <20% and ferritin <100 ng/mL
- Functional iron deficiency: TSAT <20% with ferritin >100 ng/mL
- Anemia of chronic disease: Ferritin >100 ng/mL with TSAT <20%
If ferritin is 30-100 ng/mL, suspect combined iron deficiency and chronic disease 3.
Additional Laboratory Evaluation
Complete the following tests 2, 3, 4:
- Reticulocyte count: Determines if bone marrow is responding appropriately
- Low/normal reticulocytes with anemia suggests production problem
- Elevated reticulocytes suggests hemolysis or blood loss
- Vitamin B12 and folate levels: Rule out megaloblastic anemia
- Renal function (creatinine, eGFR): Assess for renal anemia if GFR <60 mL/min/1.73 m²
- Thyroid function (TSH): Hypothyroidism causes normocytic anemia
- Stool guaiac: Rule out occult GI bleeding 4
- Peripheral blood smear review: Assess red cell morphology
Interpretation of Elevated Erythropoietin
An erythropoietin level of 37.6 mU/mL is appropriately elevated for anemia, indicating:
- Kidneys are responding normally to anemia
- This is NOT renal anemia (which shows inappropriately low EPO)
- The bone marrow may not be responding adequately to EPO stimulation
Treatment Algorithm
Step 1: Correct Identified Deficiencies
- Oral iron: 60-120 mg elemental iron daily
- IV iron if oral intolerance or functional deficiency: 10-20 mg/kg/week (max 600-1000 mg/week depending on formulation)
Vitamin deficiencies: Replace B12 or folate as indicated 3
Hypothyroidism: Treat with thyroid replacement 4
Step 2: Reassess After 4 Weeks
- Expect hemoglobin increase of ≥1 g/dL if treatment is effective
- If no response, proceed to Step 3
Step 3: Consider Erythropoietin Therapy
Indications for ESA therapy 2, 5:
- Hemoglobin remains <10 g/dL despite correcting deficiencies
- GFR <30 mL/min/1.73 m² (renal anemia)
- Symptomatic anemia affecting quality of life
- Epoetin alfa/beta: 150 IU/kg subcutaneously 3 times weekly OR 40,000-60,000 units weekly
- Darbepoetin: 2.25 mcg/kg weekly OR 150-300 mcg every 2 weeks
Prerequisites before starting ESA 5, 4:
- Ferritin ≥100 ng/mL
- TSAT ≥20%
- Supplement IV iron if functional deficiency present
Target hemoglobin: 10-12 g/dL (never exceed 12 g/dL) 5, 7
Step 4: Monitor Response
- Check hemoglobin every 2-4 weeks initially
- Discontinue ESA if no response after 8 weeks (hemoglobin increase <1 g/dL) 5, 7
- Reduce dose by 25-50% if hemoglobin rises >2 g/dL in 4 weeks or exceeds 12 g/dL 5
Critical Pitfalls to Avoid
- Do not attribute anemia to sickle cell trait alone - SCT does not cause anemia 1
- Do not start ESA without correcting iron deficiency first - This is the most common cause of ESA failure 5, 4
- Do not target hemoglobin >12 g/dL - Associated with increased cardiovascular events and mortality 8, 5, 7
- Do not continue ESA beyond 8 weeks without response - Unlikely to benefit and increases costs/risks 5, 7
- Verify iron stores before and during ESA therapy - ESAs increase iron consumption and can precipitate functional deficiency 3, 5
Special Consideration
If this patient has undiagnosed mild chronic kidney disease (common cause of elevated EPO with anemia), monitor renal function closely. With GFR <30 mL/min/1.73 m², ESA therapy becomes more clearly indicated 2, 4.